Condition: Parkinson Disease Psychosis · Amyotrophic Lateral Sclerosis (ALS) · Sponsor: 1ST Biotherapeutics, Inc.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
This description comes directly from the study's public registry record.
1STBIO information team · +82-31-895-4677 · info@1stbio.com
Always discuss trial participation with your own doctor first.
| Seoul National University | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05995782